|

A Phase 1 Study of VK2735 in Obese Adults Without Comorbidities

RECRUITINGPhase 1Sponsored by Viking Therapeutics, Inc.
Actively Recruiting
PhasePhase 1
SponsorViking Therapeutics, Inc.
Started2025-11-18
Est. completion2027-05
Eligibility
Age18 Years – 60 Years
Healthy vol.Accepted
Locations2 sites

Summary

The goal of this Phase 1, randomized, double-blind, placebo-controlled study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of VK2735 in adults who are obese (BMI ≥ 30 kg/m2) without comorbidities.

Eligibility

Age: 18 Years – 60 YearsHealthy volunteers accepted
Inclusion Criteria:

* Must be capable of giving a signed informed consent form (ICF).
* Must be medically healthy, with no significant medical history, have no clinically significant abnormalities on physical examination at Screening and/or before administration of the initial dose of IP in the opinion of the study Investigator.
* BMI ≥ 30 kg/m2.
* Willing to comply with contraceptive requirements.

Exclusion Criteria:

* Participants with any level of disease or organ system dysfunction as identified during physical examination, medical history, or laboratory testing, as assessed by the Investigator.
* Any surgical or medical condition (active or chronic) that may interfere with IP distribution, metabolism, excretion or drug absorption.
* Any condition that might compromise safety or other endpoints in the study as judged by the Sponsor (or designee) or Investigator.
* History or presence of clinically significant acute or unstable cerebrovascular (stroke), hepatic, renal, gastrointestinal, pulmonary, immunological, endocrine, hematological, oncological, or central nervous disorder that in the opinion of the Investigator would pose a significant risk for the participant.
* Current or past diagnosis of diabetes mellitus (including type 1 and type 2, except gestational diabetes).
* Have a personal or family history of medullary thyroid carcinoma (MTC) or have multiple endocrine neoplasia syndrome type 2 (MEN-2).
* Alanine aminotransferase (ALT) level or aspartate transaminase (AST) level \> 3.0 times the ULN for the reference range.
* Impaired renal function with estimated glomerular filtration rate (eGFR) \< 60 mL/min/1.73 m2 as measured at Screening.

Conditions2

Obese AdultsWeight Loss

Interventions1

Locations2 sites

California

1 site
Viking Clinical Site #001
Lake Forest, California, 92630

Florida

1 site
Viking Clinical Site #002
Miami, Florida, 33147

Find trials near these locations

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.